New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 11, 2014
08:02 EDTLJPCLa Jolla Pharmaceutical price target raised to $32 from $27 at Wedbush
Wedbush increased its price target on La Jolla after the company's GCS-100 drug facilitated statistically significant improvement in kidney function in CKD patients in a Phase 2a trial. The firm thinks the company will respond by taking the drug forward in CKD, and by activating clinical trials in multiple pipeline candidates. Wedbush keeps an Outperform rating on the stock.
News For LJPC From The Last 14 Days
Check below for free stories on LJPC the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 23, 2014
09:02 EDTLJPCLa Jolla 4.8M share Spot Secondary priced at $10.50
The deal range was $10.40-$10.60. Jefferies acted as sole book running manager for the offering.
July 22, 2014
16:01 EDTLJPCLa Jolla files to sell common stock, no amount given
La Jolla intends to use the net proceeds from the underwritten offering for general corporate purposes, funding its ongoing and future clinical trials, general and administrative expenses and potential future acquisitions and other strategic purposes. Jefferies LLC is acting as sole book-runner for the offering.
July 15, 2014
09:21 EDTLJPCOn The Fly: Pre-market Movers
Subscribe for More Information
08:01 EDTLJPCLa Jolla Pharma announces pre-clinical data for LJPC-1010 in NASH
Subscribe for More Information
July 11, 2014
11:39 EDTLJPCLa Jolla price target raised to $45 from $34 at Wedbush
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use